Abstract
Most solid cancers are treated by surgical resections to reduce the burden of disease. Surgeons often face the challenge of detecting small areas of residual neoplasm after resection or finding small primary tumors for the initial resection. Intraoperative molecular imaging (IMI) is an emerging technology with the potential to dramatically improve cancer surgery operations by allowing surgeons to better visualize areas of neoplasm using fluorescence imaging. Over the last two years, two molecular optical contrast agents received U.S. Food and Drug Administration approval, and several more drugs are now on the horizon. Thus a conference was organized at the University of Pennsylvania to bring together oncologic surgeons from different specialties to discuss the current clinical status of IMI trials with a specific focus on phase 2 and phase 3 studies. In addition, phase 1 and experimental trials were also discussed briefly, to highlight other novel techniques. Our review summarizes the discussions from the conference and delves into the types of cancers discussed, different contrast agents in human trials, and the clinical value being studied.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-8 |
| Number of pages | 8 |
| Journal | Journal of biomedical optics |
| Volume | 24 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 1 2019 |
Fingerprint
Keywords
- fluorescence-guided surgery
- intraoperative visualization
- molecular imaging
- tumor surgery
ASJC Scopus subject areas
- Electronic, Optical and Magnetic Materials
- Biomaterials
- Atomic and Molecular Physics, and Optics
- Biomedical Engineering
Cite this
Review of clinical trials in intraoperative molecular imaging during cancer surgery. / Lee, John Y.K.; Cho, Steve S.; Stummer, Walter; Tanyi, Janos L.; Vahrmeijer, Alexander L.; Rosenthal, Eben; Smith, Barbara; Henderson, Eric; Roberts, David W.; Lee, Amy; Hadjipanayis, Constantinos G.; Bruce, Jeffrey N.; Newman, Jason G.; Singhal, Sunil.
In: Journal of biomedical optics, Vol. 24, No. 12, 01.12.2019, p. 1-8.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Review of clinical trials in intraoperative molecular imaging during cancer surgery
AU - Lee, John Y.K.
AU - Cho, Steve S.
AU - Stummer, Walter
AU - Tanyi, Janos L.
AU - Vahrmeijer, Alexander L.
AU - Rosenthal, Eben
AU - Smith, Barbara
AU - Henderson, Eric
AU - Roberts, David W.
AU - Lee, Amy
AU - Hadjipanayis, Constantinos G.
AU - Bruce, Jeffrey N.
AU - Newman, Jason G.
AU - Singhal, Sunil
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Most solid cancers are treated by surgical resections to reduce the burden of disease. Surgeons often face the challenge of detecting small areas of residual neoplasm after resection or finding small primary tumors for the initial resection. Intraoperative molecular imaging (IMI) is an emerging technology with the potential to dramatically improve cancer surgery operations by allowing surgeons to better visualize areas of neoplasm using fluorescence imaging. Over the last two years, two molecular optical contrast agents received U.S. Food and Drug Administration approval, and several more drugs are now on the horizon. Thus a conference was organized at the University of Pennsylvania to bring together oncologic surgeons from different specialties to discuss the current clinical status of IMI trials with a specific focus on phase 2 and phase 3 studies. In addition, phase 1 and experimental trials were also discussed briefly, to highlight other novel techniques. Our review summarizes the discussions from the conference and delves into the types of cancers discussed, different contrast agents in human trials, and the clinical value being studied.
AB - Most solid cancers are treated by surgical resections to reduce the burden of disease. Surgeons often face the challenge of detecting small areas of residual neoplasm after resection or finding small primary tumors for the initial resection. Intraoperative molecular imaging (IMI) is an emerging technology with the potential to dramatically improve cancer surgery operations by allowing surgeons to better visualize areas of neoplasm using fluorescence imaging. Over the last two years, two molecular optical contrast agents received U.S. Food and Drug Administration approval, and several more drugs are now on the horizon. Thus a conference was organized at the University of Pennsylvania to bring together oncologic surgeons from different specialties to discuss the current clinical status of IMI trials with a specific focus on phase 2 and phase 3 studies. In addition, phase 1 and experimental trials were also discussed briefly, to highlight other novel techniques. Our review summarizes the discussions from the conference and delves into the types of cancers discussed, different contrast agents in human trials, and the clinical value being studied.
KW - fluorescence-guided surgery
KW - intraoperative visualization
KW - molecular imaging
KW - tumor surgery
UR - http://www.scopus.com/inward/record.url?scp=85076265403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076265403&partnerID=8YFLogxK
U2 - 10.1117/1.JBO.24.12.120901
DO - 10.1117/1.JBO.24.12.120901
M3 - Article
C2 - 31808327
AN - SCOPUS:85076265403
VL - 24
SP - 1
EP - 8
JO - Journal of Biomedical Optics
JF - Journal of Biomedical Optics
SN - 1083-3668
IS - 12
ER -